Prioritising drugs for single patient (n-of-1) trials in palliative care

Palliative Medicine

Volumn 23, Issue 7, 2009, Pages 623-634

  Nikles, J ^a   Mitchell, J ^a   Walters, J ^a   Hardy, J ^b   Good, P ^c   Rowett, D ^d   Shelby James, T ^e   Currow, D ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Drug; Medication; N of 1 trials; Palliative care

Indexed keywords

OPIATE; PARACETAMOL; PLACEBO;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; LONG TERM CARE; MORBIDITY; PAIN; PALLIATIVE THERAPY; PHARMACEUTICAL CARE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; PALLIATIVE CARE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 71049121008     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216309106461     Document Type: Article

References (111)

1. Mitchell, GK, Abernethy, AP A comparison of methodologies from two longitudinal community-based randomized controlled trials of similar interventions in palliative care: What worked and what did not? J Palliat Med 2005; 8: 1226-1237.
2. Jordhoy, MS, Kaasa, S., Fayers, P., Ovreness, T., Underland, G., Ahlner-Elmqvist, M. Challenges in palliative care research; recruitment, attrition and compliance: Experience from a randomized controlled trial. Palliat Med 1999; 13: 299-310.
3. Rinck, GC, van den Bos, GA, Kleijnen, J., de Haes, HJ, Schadé, E., Veenhof, CH Methodologic issues in effectiveness research on palliative cancer care: A systematic review. J Clin Oncol 1997; 15: 1697-1707.
4. Australia, PC Australia's future in palliative care research: A collaborative approach. Deakin, ACT: Palliative Care Australia; 2000.
5. Maddocks, I. Issues in the conduct of therapeutic trials in palliative care: An Australian perspective. Drugs Aging 2002; 19: 495-502.
6. Currow, D., Agar, M., Tieman, J., Abernethy, A. Multi-site research allows adequately powered palliative care trials; web-based data management makes it achievable today. Pall Med 2007; 00: 1-2.
7. Grande, GE, Todd, CJ Why are trials in palliative care so difficult? Palliat Med 2000; 14: 69-74.
8. Cook, AM, Finlay, IG, Butler-Keating, RJ Recruiting into palliative care trials: Lessons learnt from a feasibility study. Palliat Med 2002; 16: 163-165.
9. Ling, J., Rees, E., Hardy, J. What influences participation in clinical trials in palliative care in a cancer centre? Eur J Cancer 2000; 36: 621-626.
10. White, C., Hardy, J., Gilshenan, K. A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care. Supp Care Cancer 2008; 16: 1397-1405.
11. De Lima, L., Krakauer, EL, Lorenz, K., Praill, D., Macdonald, N., Doyle, D. Ensuring palliative medicine availability: The development of the IAHPC list of essential medicines for palliative care. J Pain Symptom Manage 2007; 33: 521-526.
12. Aoun, SM, Kristjanson, LJ Challenging the framework for evidence in palliative care research. Palliat Med 2005; 19: 461-465.
13. Rovers, MM, Straatman, H., Ingels, K., van der Wilt, GJ, van den Broek, P., Zielhuis, GA Generalizability of trial results based on randomized versus nonrandomized allocation of OME infants to ventilation tubes or watchful waiting. J Clin Epidemiol 2001; 54: 789-794.
14. Zucker, DR, Schmid, CH, McIntosh, MW D'agostino, RB, Selker, HP, Lau, J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol 1997; 50: 401-410.
15. Nikles, CJ, Yelland, M., Glasziou, PP, Del Mar, C. Do individualized medication effectiveness tests (n-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am J Ther 2005; 12: 92-97.
16. Nikles, CJ, Mitchell, GK, Del Mar, CB, McNairn, N., Clavarino, A. Long-term changes in management following n-of-1 trials of stimulants in attention-deficit/hyperactivity disorder. Eur J Clin Pharmacol 2007; 63: 985-989.
17. Yelland, MJ, Nikles, CJ, McNairn, N., Del Mar, CB, Schluter, PJ, Brown, RM Celecoxib compared with sustained-release paracetamol for osteoarthritis: A series of n-of-1 trials. Rheumatology (Oxford) 2007; 46: 135-140 [Epub 2006 Jun 15].
18. Nikles, CJ, Mitchell, GK, Del Mar, CB, Clavarino, A., McNairn, N. An n-of-1 trial service in clinical practice: Testing the effectiveness of stimulants for attentiondeficit/hyperactivity disorder. Pediatrics 2006; 117: 2040-2046.
19. Bruera, E., Schoeller, T., MacEachern, T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: The use of the N of 1 randomized controlled trial. J Pain Symptom Manage 1992; 7: 365-368.
20. Miller, MG, Corner, J. The 'n = 1' randomized controlled trial. Palliat Med 1999; 13: 255-259.
21. Nathan, PC, Tomlinson, G., Dupuis, LL, Greenberg, ML, Ota, S., Bartels, U., et al. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: A Bayesian randomized serial N-of-1 trials design. Support Care Cancer 2006; 14: 268-276.
22. Huber, AM, Tomlinson, GA, Koren, G., Feldman, BM Amitriptyline to relieve pain in juvenile idiopathic arthritis: A pilot study using Bayesian meta-analysis of multiple N-of-1 clinical trials. J Rheumatol 2007; 34:1125-1132 [Epub 2007 Apr 15].
23. Palter, S. Ethics of clinical trials. Semin Reprod Endocrinol 1996; 14: 85-92.
24. Dickerson, D. The 20 essential drugs in palliative care. Eur J Palliat Care 1999; 6: 130-135.
25. De Lima, L. The international association for hospice and palliative care list of essential medicines for palliative care. Palliat Med 2006; 20: 647-651.
26. Goode, PD, Currow, D., Woods, D., Tufflin, P., Ravenscroft, P. What are the essential medications in palliative care? A survey of Australian palliative care doctors. Aust Fam Phys 2006; 36: 261-264.
27. Hillner, BE, Ingle, JN, Berenson, JR, Janjan, NA, Albain, KS, Lipton, A., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18: 1378-1391.
28. Eddy, NB, Friebel, H., Hahn, KJ, Halbach, H. Codeine and its alternates for pain and cough relief. 3. The antitussive action of codeine - mechanism, methodology and evaluation. Bull World Health Organ 1969; 40: 425-454.
29. Schroeder, K., Fahey, T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2004; (4): CD001831.
30. Matthys, H., Bleicher, B., Bleicher, U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res 1983; 11: 92-100.
31. Smith, J., Owen, E., Earis, J., Woodcock, A. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006; 117: 831-835.
32. Sevelius, H., McCoy, JF, Colmore, JP Dose response to codeine in patients with chronic cough. Clin Pharmacol Ther 1971; 12: 449-455.
33. Matthys, H., Erhardt, J., Ruhle, KH Objectivation of the effect of antitussive agents using tussometry in patients with chronic cough. J Suisse de Med 1985; 115: 307-311.
34. Bentley, A., Boyd, K. Use of clinical pictures in the management of nausea and vomiting: A prospective audit. Palliat Med 2001; 15: 247-253.
35. Thomson Healthcare, Inc, (ed). Micromedex healthcare series. Thomson Micromedex; 2007.
36. Olson, LG, Ambrogetti, A., Sutherland, DC A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. Psychosomatics 2003; 44: 38-43.
37. Wagner, GJ, Rabkin, R. Effects of dextroamphetamine on depression and fatigue in men with HIV: A double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61: 436-440.
38. Corey, PJ, Heck, AM, Weathermon, RA Amphetamines to counteract opioid-induced sedation. Ann Pharmacother 1999; 33: 1362-1366.
39. Reissig, JE, Rybarczyk, AM Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 2005; 39: 727-731.
40. Yee, JD, Berde, CB Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 1994; 9: 122-125.
41. Mier, RJ, Bachrach, SJ, Lakin, RC, Barker, T., Childs, J., Moran, M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154: 1214-1218.
42. Blasco, PA, Stansbury, JC Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996; 150: 932-935.
43. Stern, LM Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997; 33: 52-54.
44. Rashid, H., Long, JD, Wadleigh, RG Management of secretions in esophageal cancer patients with glycopyrrolate. Ann Oncol 1997; 8: 198-199.
45. Strutt, R., Fardell, B., Chye, R. Nebulized glycopyrrolate for drooling in a motor neuron patient. J Pain Symptom Manage 2002; 23: 2-3.
46. Fontaine, R., Mercier, P., Beaudry, P., Annable, L., Chouinard, G. Bromazepam and lorazepam in generalized anxiety: A placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 1986; 74: 451-458.
47. Ruiz, AT A double-blind study of alprazolam and lorazepam in the treatment of anxiety. J Clin Psychiatry 1983; 44: 60-62.
48. Zung, WW, Daniel Jr, JT, King, RE, Moore, DT A comparison of prazepam, diazepam, lorazepam and placebo in anxious outpatients in non-psychiatric private practices. J Clin Psychiatry 1981; 42: 280-284.
49. McCurdy, L. Lorazepam, a new benzodiazepine derivative, in the treatment of anxiety: A double-blind clinical evaluation. Am J Psychiatry 1979; 136: 187-190.
50. Battelli, T., Bonsignori, M., Manocchi, P., Rossi, G. Anxiety therapy in the neoplastic patient. Curr Med Res Opin 1976; 4: 185-188.
51. Bruera, E., Valero, V., Driver, L., Shen, L., Willey, J., Zhang, T., et al. Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24: 2073-2078.
52. Hanna, A., Sledge, G., Mayer, ML, Hanna, N., Einhorn, L., Monahan, P., et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006; 14: 210-215.
53. Bruera, E., Driver, L., Barnes, EA, Willey, J., Shen, L., Palmer, JL, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol 2003; 21: 4439-4443.
54. Sugawara, Y., Akechi, T., Shima, Y., Okuyama, T., Akizuki, N., Nakano, T., et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: A preliminary study. Palliat Med 2002; 16: 261-263.
55. Bruera, E., Fainsinger, R., MacEachern, T., Hanson, J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50: 75-77.
56. Wilwerding, MB, Loprinzi, CL, Mailliard, JA, O'Fallon, JR, Miser, AW, van Haelst, C., et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3: 135-138.
57. Blockmans, D., Persoons, P., Van Houdenhove, B., Bobbaers, H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med 2006; 119: 167.e23-167.e30.
58. Breitbart, W., Rosenfeld, B., Kaim, M., Funesti-Esch, J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161: 411-420.
59. Kraus, MF, Burch Jr, EA Methylphenidate hydrochloride as an antidepressant: Controversy, case studies, and review. South Med J 1992; 85: 985-991.
60. Macleod, AD Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16: 193-198.
61. Olin, J., Masand, P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37: 57-62.
62. Sood, A., Barton, DL, Loprinzi, CL Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006; 23: 35-40.
63. Homsi, J., Nelson, KA, Sarhill, N., Rybicki, L., LeGrand, SB, Davis, MP, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001; 18: 403-407.
64. Orr, K., Taylor, D. Psychostimulants in the treatment of depression: A review of the evidence. CNS Drugs 2007; 21: 239-257.
65. Wallace, AE, Kofoed, LL, West, AN Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152: 929-931.
66. Lee, H., Kim, S-W., Kim, J-M., Shin, I-S., Yang, S-J., Yoon, J-S. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol 2005; 20: 97-104.
67. Grade, C., Redford, B., Chrostowski, J., Toussaint, L., Blackwell, B. Methylphenidate in early poststroke recovery: A double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998; 79: 1047-1050.
68. Camacho, A., Ng, B. Methylphenidate for alpha-interferon induced depression. J Psychopharmacol 2006; 20: 687-689.
69. Jansen, IH, Olde Rikkert, MG, Hulsbos, HA, Hoefnagels, WH Toward individualized evidence-based medicine: Five "N of 1" trials of methylphenidate in geriatric patients. J Am Geriatr Soc 2001; 49: 474-476.
70. Lavretsky, H., Park, S., Siddarth, P., Kumar, A., Reynolds 3rd, CF. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14: 181-185.
71. Patkar, AA, Masand, PS, Pae, C-U., Peindl, K., Hooper-Wood, C., Mannelli, P., et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26: 653-656.
72. Fernandez, F., Levy, JK, Samley, HR, Pirozzolo, FJ, Lachar, D., Crowley, J., et al. Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine. Int J Psychiatry Med 1995; 25: 53-67.
73. Bruera, ED, MacEachern, TJ, Spachynski, KA, LeGatt, DF, MacDonald, RN, Babul, N., et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 1994; 74: 3204-3211.
74. Bruera, E., Belzile, M., Neumann, C., Harsanyi, Z., Babul, N., Darke, A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Sympt Manage 2000; 19: 427-435.
75. Saleh, JW, Lebwohl, P. Metoclopramide-induced gastric emptying in patients with anorexia nervosa. The Am J Gastroenterol 1980; 74: 127-132.
76. Navigante, AH, Cerchietti, LC, Castro, MA, Lutteral, MA, Cabalar, ME Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006; 31: 38-47.
77. Gremaud, G., Zulian, GB Indications and limitations of intravenous and subcutaneous midazolam in a palliative care center (1). J Pain Symptom Manage 1998; 15: 331-333.
78. Bottomley, DM, Hanks, GW Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990; 5: 259-261.
79. Burke, AL, Diamond, PL, Hulbert, J., Yeatman, J., Farr, EA Terminal restlessness - Its management and the role of midazolam. Med J Australia 1991; 155: 485-487.
80. Theobald, DE, Kirsh, KL, Holtsclaw, E., Donaghy, K., Passik, SD An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23: 442-447.
81. Sorensen, M., Jorgensen, J., Viby-Mogensen, J., Bettum, V., Dunbar, GC, Steffensen, K. A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985; 71: 339-346.
82. Bicopoulos, D. Pharmaceutical Care Information Services. AusDI: Australian drug information for the health care professional. 2nd ed. Castle Hill, NSW: Pharmaceutical Care Information Services Pty Ltd.; 2002.
83. Timmer, CJ, Ad Sitsen, JM, Delbressine, LP Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461-474.
84. Rutherford, RM, Azher, T., Gilmartin, JJ Dramatic response to nebulized morphine in an asthmatic patient with severe chronic cough. Irish Med J 2002; 95: 113-114.
85. Stein, WM, Min, YK Nebulized morphine for paroxysmal cough and dyspnea in a nursing home resident with metastatic cancer. Am J Hosp Palliat Care 1997; 14: 52-56.
86. Jackson, WC, Tavernier, L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med 2003; 6: 251-255.
87. Passik, SD, Lundberg, J., Kirsh, KL, Theobald, D., Donaghy, K., Holtsclaw, E., et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Sympt Manage 2002; 23: 526-532.
88. Jakovljevi, M., Sagud, M., Mihaljevi-Peles, A. Olanzapine in the treatment-resistant, combat-related PTSD - a series of case reports. Acta Psychiat Scand 2003; 107: 394-396 [discussion 396].
89. Sharple, AL, Attenburrow, MEJ, Hafizi, S., Cowen, PJ Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005; 66: 450-454.
90. Stein, MB, Kline, NA, Matloff, JL Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry 2002; 159: 1777-1779.
91. McEvoy, GK, (ed). AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2007.
92. Cole, RM, Robinson, F., Harvey, L., Trethowan, K., Murdoch, V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Sympt Manage 1994; 9: 48-50.
93. Weschules, DJ, Maxwell, T., Reifsnyder, J., Knowlton, CH Are newer, more expensive pharmacotherapy options associated with superior symptom control compared to less costly agents used in a collaborative practice setting? Am J Hosp Palliat Care 2006; 23: 135-149.
94. Macleod, AD Ondansetron in multiple sclerosis. J Pain Sympt Manage 2000; 20: 388-391.
95. Mercadante, S., Sapio, M., Serretta, R. Ondansetron in nausea and vomiting induced by spinal morphine. J Pain Sympt Manage 1998; 16: 259-262.
96. Pereira, J., Bruera, E. Successful management of intractable nausea with ondansetron: A case study. J Palliat Care 1996; 12: 47-50.
97. Brennan, MT, Shariff, G., Lockhart, PB, Fox, PC Treatment of xerostomia: a systematic review of therapeutic trials. Dent Clin North Am 2002; 46: 847-856.
98. Taweechaisupapong, S., Pesee, M., Aromdee, C., Laopaiboon, M., Khunkitti, W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J 2006; 51: 333-337.
99. Vivino, FB, Al-Hashimi, I., Khan, Z., LeVeque, FG, Salisbury 3rd, PL, Tran-Johnson, TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Inter Med 1999; 159: 174-181.
100. Rhodus, NL, Schuh, MJ Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1991; 72: 545-549.
101. Rieke, JW, Hafermann, MD, Johnson, JT, LeVeque, FG, Iwamoto, R., Steiger, BW, et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 1995; 31: 661-669.
102. Nyarady, Z., Nemeth, A., Ban, A., Mukics, A., Nyarady, J., Ember, I., et al. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Anticancer Res 2006; 26: 1557-1562.
103. Gotrick, B., Akerman, S., Ericson, D., Torstenson, R., Tobin, G. Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res 2004; 83: 393-397.
104. Haddad, P., Karimi, M. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiother Oncol 2002; 64: 29-32.
105. Johnson, JT, Ferretti, GA, Nethery, WJ, Valdez, IH, Fox, PC, Ng, D., et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Eng J Med 1993; 329: 390-395.
106. Davies, AN, Daniels, C., Pugh, R., Sharma, K. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med 1998; 12: 105-111.
107. Dakkak, M., Jones, BP, Scott, MG, Tooley, PJ, Bennett, JR Comparing the efficacy of cisapride and ranitidine in oesophagitis: A double-blind, parallel group study in general practice. Br J Clin Pract 1994; 48: 10-14.
108. Smoller, JW, Pollack, MH, Systrom, D., Kradin, RL Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998; 39: 24-29.
109. Hirst, A., Sloan, R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev 2002; (4): CD003346.
110. Jamieson, AO, Zammit, GK, Rosenberg, RS, Davis, JR, Walsh, JK Zolpidem reduces the sleep disturbance of jet lag. Sleep Med 2001; 2: 423-430.
111. Stockler, M., Vardy, J., Pillai, A., Warr, D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: A randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004; 22: 3389-3394.